Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer
medicine. Here, we review data and technologies that have revealed intra-tumor …

Cancer is the leading cause of death worldwide. The complex and disorganized tumor
microenvironment makes it very difficult to treat this disease. The most common in vitro drug …

Toward development of a precision medicine framework for metastatic, castration-resistant
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …

There is substantial heterogeneity among primary prostate cancers, evident in the spectrum
of molecular abnormalities and its variable clinical course. As part of The Cancer Genome …

Many primary-tumor subregions have low levels of molecular oxygen, termed hypoxia.
Hypoxic tumors are at elevated risk for local failure and distant metastasis, but the molecular …

Prostate tumours are highly variable in their response to therapies, but clinically available
prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 …

Herein we provide a detailed molecular analysis of the spatial heterogeneity of clinically
localized, multifocal prostate cancer to delineate new oncogenes or tumor suppressors. We …

Importance The molecular landscape underpinning response to the androgen receptor (AR)
antagonist enzalutamide in patients with metastatic castration-resistant prostate cancer …

Abstract Background TP53, PTEN, and RB1 tumor suppressor genes (TSGs) are recurrently
altered in treatment-resistant prostate cancer. Cooperative loss of two or more TSGs may …

Neuroendocrine prostate cancer (NEPC), a lethal form of the disease, is characterized by
loss of androgen receptor (AR) signaling during neuroendocrine transdifferentiation, which …